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Abstract
Background: Offspring of women with type 1 diabetes are at increased risk of fetal growth patterns which are
associated with perinatal morbidity. Our aim was to compare rates of large- and small-for-gestational age (LGA;
SGA) defined according to different criteria, using data from the Continuous Glucose Monitoring in Type 1 Diabetes
Pregnancy Trial (CONCEPTT).
Methods: This was a pre-specified analysis of CONCEPTT involving 225 pregnant women and liveborn infants from
31 international centres (ClinicalTrials.gov NCT01788527; registered 11/2/2013). Infants were weighed immediately at
birth and GROW, INTERGROWTH and WHO centiles were calculated. Relative risk ratios, sensitivity and specificity
were used to assess the different growth standards with respect to perinatal outcomes, including neonatal
hypoglycaemia, hyperbilirubinaemia, respiratory distress, neonatal intensive care unit (NICU) admission and a
composite neonatal outcome.
Results: Accelerated fetal growth was common, with mean birthweight percentiles of 82.1, 85.7 and 63.9 and LGA
rates of 62, 67 and 30% using GROW, INTERGROWTH and WHO standards respectively. Corresponding rates of SGA
were 2.2, 1.3 and 8.9% respectively. LGA defined according to GROW centiles showed stronger associations with
preterm delivery, neonatal hypoglycaemia, hyperbilirubinaemia and NICU admission. Infants born > 97.7th centile
were at highest risk of complications. SGA defined according to INTERGROWTH centiles showed slightly stronger
associations with perinatal outcomes.
Conclusions: GROW and INTERGROWTH standards performed similarly and identified similar numbers of neonates
with LGA and SGA. GROW-defined LGA and INTERGROWTH-defined SGA had slightly stronger associations with
neonatal complications. WHO standards underestimated size in preterm infants and are less applicable for use in
type 1 diabetes.
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Background
Birth weight is an important indicator of neonatal well-
being [1, 2]. Infants who are small- or large-for-
gestational-age (SGA or LGA; birth weight < 10th or
>90th percentile) experience higher risks of morbidity
and mortality [3, 4]. Recent population based data sug-
gests that despite improvements in care, infants of
women with type 1 diabetes (T1D) remain at high risk
of LGA (rates ~ 50%) [5]. LGA rates were also high in
the CONCEPTT international randomized controlled
trial of the use of continuous glucose monitoring (CGM)
in comparison with capillary blood glucose monitoring
in pregnant women with T1D [6]. LGA rates were sig-
nificantly reduced in infants of women who used CGM
(53% vs 69% in home blood glucose monitoring group),
likely due to improved glycaemic control [7].
Currently there is controversy internationally about
which growth standards to use to compare LGA rates in
different populations. Customised (Gestation Related
Optimum Weight; GROW) centiles [8] were used in
CONCEPTT for the comparison of birthweight across
international sites and diagnosis of LGA. GROW centiles
are customised to maternal and neonatal factors includ-
ing maternal ethnicity, height, weight, parity, neonatal
sex and gestational age [7, 9]. GROW provides country-
specific customised centiles, enabling international com-
parisons between populations. Advocates suggest that
customised centiles reduce over-investigation of normal
fetuses and can more accurately predict fetuses at in-
creased risk of stillbirth and perinatal mortality [9, 10].
Other growth standards based on data from the INTE
RGROWTH-21st study (20,486 infants across eight geo-
graphical areas) and the World Health Organisation
(WHO) Multicentre Growth Reference Study (8500 in-
fants across six geographical areas) [11, 12] are used
internationally. Both standards assume < 3.5% of the
variability in growth is due to differences in ethnicity
and population when circumstances are optimal (e.g
healthy, well-nourished mothers) [13]. INTE
RGROWTH-21st standards focus on fetal growth and
neonatal size at birth, while the WHO charts assess
weight-for-age at 0–60 months [12]. In addition, some
studies in diabetes pregnancy report standard deviation
(SD) based birthweight categorisation.
Population studies comparing growth standards have
focused on the identification of SGA in general mater-
nity populations [9, 10, 14]. However, in infants of
women with T1D, LGA is five times more common than
in the background maternity population [5]. Identifica-
tion of these infants may improve outcomes by increas-
ing surveillance and targeting interventions to those at
highest risk [15]. Furthermore, identification of a single
growth standard with optimal performance in T1D preg-
nancies would allow future standardisation of research
outcomes.
A further challenge in growth assessment in T1D
pregnancy regards the use of growth standards in pre-
term infants. GROW and INTERGROWTH approach
preterm growth differently. GROW centiles are based
upon the Hadlock formula for gestational age, suggesting
that the growth of preterm and term infants should be
exactly the same at any timepoint [16]. The INTE
RGROWTH standards do not make this assumption and
are based on the size of preterm infants at birth. Al-
though this approach seems more scientifically justifi-
able, as growth abnormalities may contribute to preterm
birth, the INTERGROWTH standards were based upon
limited data from preterm (before 37 weeks) and very
preterm babies (before 34 weeks), which introduces un-
certainty [17]. More studies in preterm infants are
needed to identify which growth standard performs best
in this group [18].
Our aim was therefore to assess the incidence of LGA
and SGA using different definitions and growth stan-
dards in T1D pregnancy, and to assess which standard
was able to identify infants at highest risk of perinatal
complications.
Methods
The recruitment, rationale and methodology of the
CONCEPTT trial are described in detail elsewhere [6]
(ClinicalTrials.gov NCT01788527; registered 11/2/2013;
see Appendix S1 for CONCEPTT collaborative group).
In brief, women with T1D were recruited before or dur-
ing pregnancy and randomized to real-time continuous
glucose monitoring or capillary glucose monitoring
alone. Women in the capillary glucose monitoring group
also had short periods of masked continuous glucose
monitoring, to allow comparison of glycaemic control
between groups. Women were followed-up until delivery
with collection of information about birth outcomes.
Local policies in the study sites were used to determine
the optimal timing and method of delivery.
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Pre-specified neonatal outcomes for the CONCEPTT
study included miscarriage, stillbirth, neonatal death,
birth injury, shoulder dystocia, preterm delivery, neo-
natal hypoglycaemia requiring intravenous dextrose,
hyperbilirubinaemia, respiratory distress syndrome, neo-
natal intensive care unit admission requiring a duration
of at least 24 h, total length of hospital stay, birthweight,
macrosomia (birthweight ≥4 kg), LGA (>90th centile)
and SGA (< 10th centile) based on customised centiles.
Definitions for CONCEPTT outcomes are given in Ap-
pendix S2 and were standardised across all the CON-
CEPTT sites. This data was collected using participant’s
medical records. For the CONCEPTT trial, the compos-
ite neonatal endpoint incorporated pregnancy loss (mis-
carriage, stillbirth, or neonatal death), birth injury,
neonatal hypoglycaemia, hyperbilirubinaemia, respiratory
distress syndrome, or neonatal intensive care admis-
sion> 24 h. This pre-specified secondary analysis includes
data from pregnant and pre-pregnant recruits who be-
came pregnant during the 6-month pre-pregnancy trial
and who gave birth to a liveborn infant. Therefore, in
the current study, the composite neonatal endpoint in-
corporated birth injury, neonatal hypoglycaemia, hyper-
bilirubinaemia, respiratory distress syndrome, or
neonatal intensive care admission> 24 h but not preg-
nancy loss.
Calculation of birth weight centiles
Gestational age at delivery was based upon ultrasound
measurements in early pregnancy (approximately 12
weeks). Maternal height and weight required for the
GROW calculation was measured by trained staff at the
baseline study visit. As the CONCEPTT study recruited
women in early pregnancy, this was considered broadly
similar to pre-pregnancy weight.
GROW centiles were calculated using version 8 (2017)
of the GROW calculator using data about maternal self-
reported ethnicity, parity, height, weight, gestational age
at birth and neonatal sex [8]. INTERGROWTH centiles
were calculated using the windows app (available at
https://intergrowth21.tghn.org/intergrowth-21st-
applications/; accessed 31/03/2019) using information
about infant sex, weight and age (0–60 months). WHO
centiles were calculated using data about infant sex,
weight and age (0 months) using the igrowup package
for Stata (available at http://www.who.int/childgrowth/
software/en/; accessed 31/03/2019). To demonstrate dif-
ferences and similarities between centile-based methods
and SD-based methods in the assessment of birth
weight, we also included SD-based definitions for LGA
(+ 1 and 2 SDs) using methods which were commonly
used in the literature. Calculation of SGA using defini-
tions <5th and < 2.5th percentile resulted in too few in-
fants to permit meaningful analysis.
Statistical analysis
Continuous data were described as mean (SD) and cat-
egorical data as n (%) as appropriate. Data regarding
birthweight were analysed as percentiles. An unadjusted
log-binomial regression model was used to assess associ-
ations between different growth standards, at different
thresholds, and perinatal outcomes. Results are pre-
sented as relative risk ratios (RR) and 95% confidence in-
tervals. As other comparable studies in the literature
provide odds ratios, we have included a table in the sup-
plementary material with odds ratios and 95% confi-
dence intervals, calculated using unadjusted logistic
regression (Table S1). The threshold for statistical sig-
nificance was p< 0.05. We considered that the best per-
forming growth standard to be that which was
significantly associated with the most suboptimal peri-
natal outcomes.
Results
Two hundred twenty-five women and infants were in-
cluded in this analysis, including 200 from the pregnancy
arm and 25 from the pre-pregnancy arm who became
pregnant during the trial. Baseline characteristics and
pregnancy outcomes are detailed in Table 1. Most
women were over 30 years old (mean age 31.4 years),
overweight (mean BMI 25.8 kg/m2), of European or
Mediterranean ethnicity (86.2%) and approximately half
used insulin pump therapy (48.9%). They had T1D of
16.5 years’ duration with suboptimal glucose levels
(HbA1c 6.9%; 51.8 mmol/mol) in early pregnancy as de-
fined by the trial eligibility criteria, which required
HbA1c >=6.5% (48 mmol/mol). Their infants were born
at 37.0 weeks of gestation, predominantly by Caesarean
section (68.9%).
Large-for-gestational-age (LGA) rates varied (Table 2.
GROW: 62.2%; INTERGROWTH 66.7%; WHO 29.8%)
and there were also differences in the mean and median
birthweight centile (Table 1. Mean centiles GROW: 82.1;
INTERGROWTH 85.7; WHO 63.9 centiles; Median cen-
tiles GROW: 95.2; INTERGROWTH 95.0; WHO 73.6
centiles). Other measures of birth weight are shown in
Table 2. Other common perinatal complications in-
cluded neonatal hypoglycaemia (25.3%), hyperbilirubi-
naemia (27.6%), respiratory distress (8.4%) which all
contributed to frequent NICU admissions > 24 h (36.9%).
Birth injury and shoulder dystocia were uncommon, (1/
225 (0.4%)) and only occurred in one infant who was
considered LGA by all criteria. LGA according to
GROW, INTERGROWTH and WHO criteria was asso-
ciated with increased risks of perinatal complications
(Table 2). While each growth standard was associated
with some complications, no growth standard identified
all complications studied. Increased birthweight accord-
ing to GROW displayed more significant associations
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with perinatal outcomes than INTERGROWTH (i.e.
with neonatal hypoglycemia, hyperbilirubinemia, NICU
admission and the composite outcome).
Most perinatal complications demonstrated a U-shaped
relationship with the birth centile (Fig. 1). Neonatal
hypoglycaemia was most frequent in infants born ex-
tremely large for gestational age (ELGA; > 97.7th centile).
In smaller infants (<25th centile), GROW and INTE
RGROWTH were associated with hyperbilirubinaemia,
while WHO centiles at < 10th and/or <25th centile
thresholds were associated with multiple outcomes, in-
cluding NICU admission, hyperbilirubinaemia, respiratory
distress and the composite outcome (Table 2; Fig. 1).
Overall GROW and INTERGROWTH standards per-
formed similarly and identified similar numbers with
LGA (slightly higher for INTERGROWTH) and SGA
(slightly higher for GROW). These standards performed
consistently regardless of sex, ethnicity and timing of de-
livery (see supporting Tables S2, S3, S4). The positive
and negative predictive values of the neonatal outcomes
and their associated sensitivity and specificity varied de-
pending on outcome (Table 3). The WHO standards do
not take gestational age at birth into account and there-
fore underestimated size in preterm infants. This re-
sulted in a linear association between WHO centile and
preterm delivery (Fig. 1).
Table 1 Maternal Infant Characteristics. BMI: body mass index; GROW: gestation related optimum weight; NICU: neonatal intensive
care unit; WHO: World Health Organisation. Composite outcome: birth injury, neonatal hypoglycaemia, hyperbilirubinaemia,
respiratory distress syndrome, or neonatal intensive care admission. Diabetes complications defined as any retinopathy, neuropathy
or nephropathy
Mean (SD) or n (%)
n=225
MATERNAL CHARACTERISTICS
Maternal age, years 31.4 (4.5)
BMI at enrolment, kg/m2 25.8 (4.6)
Ethnicity European/ Mediterranean origin 194 (86.2)
Primiparous 89 (39.6)
Duration of diabetes, years 16.5 (7.7)
Diabetes complications 58 (25.8)
Hypertension pre-pregnancy 15 (6.7)
HbA1c at randomisation mmol/mol 51.8 (6.6)
HbA1c at randomisation % 6.9 (0.6)
Smoking 20 (8.9)
Insulin pump 110 (48.9)
INFANT CHARACTERISTICS
Sex (% male) 115 (51.1)
Gestational age at delivery 37.0 (1.6)
BIRTHWEIGHT MEASURES
Birthweight g 3583.6 (705)
Macrosomia >=4 kg 59 (26.2) Median (range)
GROW centile 82.1 (25.9) 95.2 (0.1–100.0)
INTERGROWTH centile 85.7 (20.8) 95.0 (3.9–100.0)
WHO centile 63.9 (32.0) 73.6 (0.0–100.0)
OBSTETRIC AND PERINATAL OUTCOMES
Caesarean section 155 (68.9)
Preterm delivery 89 (39.6)
Neonatal hypoglycaemia requiring intravenous dextrose 57 (25.3)
NICU admission 83 (36.9)
Hyperbilirubinaemia 62 (27.6)
Respiratory distress 19 (8.4)
Composite neonatal outcome 107 (47.6)
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Discussion
This study demonstrates that GROW and INTE
RGROWTH growth standards perform comparably in
type 1 diabetes pregnancies, giving similar median birth-
weight centiles and comparable rates of LGA and SGA
neonates. Furthermore, both GROW and INTE
RGROWTH defined LGA identified neonates at in-
creased risk of complications. LGA defined according to
GROW (>90th and/or > 97.7th centile) showed stronger
associations with preterm delivery, neonatal
hypoglycaemia, hyperbilirubinaemia and NICU
admission. In smaller infants, SGA defined according to
INTERGROWTH criteria showed slightly stronger asso-
ciations with outcomes. However, using any thresholds
studied, weight related measures alone were not strong
predictors of suboptimal perinatal outcomes (Table 3).
WHO standards do not incorporate gestational age at
delivery, and thus fail to adequately describe size at birth
in preterm infants. For term infants, the WHO criteria
gave a true birthweight centile, but for preterm infants,
the WHO criteria gave a low centile, which reflected
their prematurity, not their comparative size at birth.
Table 2 Association of adverse neonatal outcomes with low and high birthweights after GROW, INTERGROWTH and WHO criteria.
Relative risk ratios and 95% confidence intervals are reported in comparison to all other pregnancies. Neonatal hypoglycaemia
included only infants who required IV dextrose. GROW: gestation related optimum weight; NICU: neonatal intensive care unit; WHO:
world health organisation. Composite outcome: birth injury, neonatal hypoglycaemia, hyperbilirubinaemia, respiratory distress















Birthweight > 84.1st centile (mean + 1 sd)
GROW > 84.1st centile 146/225
(64.9%)
1.66 (0.97 to 2.84) 1.41 (0.95 to
2.10)





1.45 (0.81 to 2.61) 1.17 (0.77 to
1.77)
1.19 (0.71 to 1.99) 1.30 (0.45 to 3.77) 1.20 (0.85 to 1.69)
WHO > 84.1st centile 82/225
(36.4%)
1.36 (0.87 to 2.13) 0.99 (0.69 to
1.41)
0.77 (0.48 to 1.23) 0.80 (0.32 to 2.04) 1.00 (0.75 to 1.33)
Birthweight >90th centile (mean + 1.28 sd)
GROW >90th centile 140/225
(62.2%)
1.86 (1.09 to 3.20)* 1.49 (1.01 to
2.21)*






1.69 (0.97 to 2.94) 1.48 (0.98 to
2.22)
1.44 (0.87 to 2.36) 1.88 (0.64 to 5.45) 1.41 (1.01 to 1.96)*
WHO >90th centile 67/225
(29.8%)
1.48 (0.94 to 2.33) 1.02 (0.70 to
1.47)
0.82 (0.50 to 1.34) 0.63 (0.22 to 1.82) 1.05 (0.78 to 1.41)
Birthweight > 97.7th centile (mean + 2 sd)
GROW > 97.7th centile 95/225
(42.2%)
2.35 (1.47 to 3.75)*** 1.62 (1.15 to
2.28)**






2.30 (1.45 to 3.65)*** 1.48 (1.06 to
2.08)*
1.19 (0.78 to 1.82) 1.61 (0.68 to 3.80) 1.42 (1.08 to 1.86)*
WHO > 97.7th centile 28/225
(12.4%)
2.29 (1.45 to 3.61)*** 1.55 (1.05 to
2.30)*
0.90 (0.45 to 1.77) 1.32 (0.41 to 4.24) 1.33 (0.95 to 1.86)
Birthweight <10th centile (<1.28 sd below mean)
GROW <10th centile 5/225 (2.2%) 0.79 (0.13 to 4.60) 1.65 (0.79 to
3.45)
2.24 (1.06 to 4.73)* 2.44 (0.40 to
14.91)
1.27 (0.61 to 2.63)
INTERGROWTH <10th
centile
3/225 (1.3%) Insufficient events 1.83 (0.81 to
4.14)
2.47 (1.08 to 5.65)* 4.11 (0.78 to
21.63)
1.41 (0.63 to 3.18)
WHO <10th centile 20/225 (8.9%) 1.21 (0.59 to 2.45) 1.90 (1.31 to
2.77)***




Birthweight <25th centile (< 0.675 sd below mean)
GROW <25th centile 13/225 (5.8%) 0.59 (0.16 to 2.17) 1.05 (0.51 to
2.13)
1.43 (0.69 to 2.95) 1.92 (0.50 to 7.43) 0.80 (0.40 to 1.61)
INTERGROWTH <25th
centile
7/225 (3.1%) 0.56 (0.09 to 3.46) 1.58 (0.81 to
3.07)
2.15 (1.09 to 4.23)* 3.66 (1.04 to
12.88)*
1.21 (0.63 to 2.33)
WHO <25th centile 37/225
(16.4%)
1.22 (0.70 to 2.12) 1.83 (1.31 to
2.57)***
1.77 (1.13 to 2.76)* 2.96 (1.25 to
7.02)*
1.22 (0.70 to 2.12)
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This measure of prematurity means that the WHO cri-
teria were still able to predict outcomes, which demon-
strates the importance of preterm delivery in relation to
multiple neonatal complications. However, the inability
to reliably attribute a birthweight centile is a substantial
limitation in type 1 diabetes pregnancies, where rates of
preterm delivery are as high as 40% [5].
A central aspect to the controversy about GROW and
INTERGROWTH centiles involves the perceived im-
portance of maternal factors to the growth of the infant,
and ethnicity in particular. Proponents of GROW
customised centiles believe that incorporating maternal
variables results in a more accurate representation of
size at birth [9, 19]. Conversely, proponents of the INTE
RGROWTH-21st standards claim that variables such as
ethnicity make little difference to size at birth, in well-
nourished populations with access to adequate antenatal
care [13]. A limitation of the CONCEPTT trial is that
while it international, 86% of women recruited were of
European / Mediterranean origin, which reduced the op-
portunity to look at growth standard performance in dif-
ferent ethnicities. A further issue is that women who
Fig. 1 Rates (%) of caesarean delivery, preterm delivery, neonatal hypoglycaemia, hyperbilirubinaemia, respiratory distress, NICU admission and
the composite neonatal outcome according to birth centile category based on GROW, INTERGROWTH and WHO standards. Numbers in each
category are given at the bottom right of this figure
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choose to participate in studies are often affluent, well-
nourished and educated, and may not represent mothers
with different socioeconomic circumstances.
A major focus for growth standards has been on the
identification of infants who are SGA with a view to re-
ducing stillbirth rates [9]. Although we have identified
that infants <25th centile displayed a trend to be at high-
est risk of multiple complications, very few infants fell
into this category which made detailed assessment of
SGA outcomes challenging. Although SGA is uncom-
mon in type 1 diabetes pregnancy, it is plausible that in-
fants born < 10th centile do not represent all those with
growth restriction.
In this study, standard-deviation-based criteria for the
diagnosis of LGA have been assessed. Although a birth
weight z score > 1 is considered consistent with LGA,
this definition is different to standard centile-based defi-
nitions (>90th centile) [20]. Different approaches to the
LGA diagnosis contribute to difficulty in comparing
populations internationally [21–23].
A fundamental aim of antenatal care in T1D pregnan-
cies involves careful control of maternal glycaemia to
normalise fetal growth. This study shows that growth –
related measures alone are not strong predictors of sub-
optimal perinatal outcomes. For example, a birthweight
>90th centile on GROW and INTERGROWTH criteria
could identify neonatal hypoglycaemia, NICU admission
and respiratory distress with 71–77% sensitivity, but the
specificity for these outcomes was around 32–42%.
These data are consistent with other work which high-
lights the challenges of accurate prediction of neonatal
outcomes in T1D pregnancy. For example, Yamamoto
and colleagues demonstrated that LGA was the only sig-
nificant predictor for neonatal hypoglycaemia on ad-
justed logistic regression analysis (odds ratio 2.51, 95%
CI 1.10–5.70) [24]. However, 36% of infants with neo-
natal hypoglycaemia were appropriate for gestational
age, resulting in similar levels of sensitivity and specifi-
city seen in the current report.
As only a small proportion of the general maternity
population has type 1 diabetes, CONCEPTT represents
one of the larger randomised trials with detailed data on
perinatal outcomes, making it useful to assess fetal
growth, and infant birthweight outcomes. Customised
(GROW) centiles were reported for CONCEPTT, but
the effect of the intervention was also seen using INTE
RGROWTH standards. Although accelerated fetal
growth is common in T1D pregnancies, the rates of
LGA in the CONCEPTT infants were higher than ex-
pected (66% in CONCEPTT compared to ~ 50% in a UK
population using similar methodology [5]). The reasons
for this are unclear, particularly as the CONCEPTT
population had better glycaemic control compared to
the UK clinical population [5].
Despite maternal diabetes being a risk factor of peri-
natal morbidity, there has been relatively little assess-
ment of different growth standards in this population.
Kase and colleagues reported that customised centiles
identified more infants as SGA/LGA compared to popu-
lation centiles in diabetes pregnancies [25]. Narchi and
Skinner had similar findings but concluded there was no
evidence of a difference in mortality or morbidity be-
tween the infants identified by customised vs population
growth standards [26]. The current study adds to the lit-
erature by highlighting differences between the common
growth standards in a generalisable population of preg-
nant women with type 1 diabetes. We had no women
with optimal glucose control (defined as HbA1c< 48
mmol/mol) in early pregnancy as these women were ex-
cluded from the CONCEPTT trial. However, population
based studies confirm that only 15% of women with
T1D achieve a first trimester HbA1c level < 6.5% (48
mmol/mol [5]) and thus the data presented here is rep-
resentative for the vast majority of women. Future stud-
ies should evaluate growth standards and definitions of
LGA and SGA in larger cohorts of women with diabetes,
including among women with target HbA1c levels. Bet-
ter understanding of the causes and early identification
of growth restriction in diabetes pregnancy should be a
research priority.
Conclusions
WHO growth standards do not incorporate gestational
age at birth and therefore are unsuitable for use in type
1 diabetes pregnancy, where preterm delivery is com-
monplace. However, GROW and INTERGROWTH
standards are both suitable. Infants born > 97.7th centile
had the highest risks of suboptimal outcomes. LGA de-
fined by GROW and SGA defined by INTERGROWTH
showed strongest associations with neonatal outcomes.
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